As patients are increasingly being asked to give themselves their own injections, Noble Rx Marketing, an Orlando firm that makes training devices to aid drug delivery, is expanding into the global biologics market.
Biologics are medicines that use biological processes or living cells to treat disease. Examples include vaccines or gene therapy. Because they involve living cells, biologic drugs must be injected, a job more patients are doing themselves.
The injection market has grown 14 percent over last year, according to Noble CEO Jeff Baker, who sees the trend as a call for more patient training tools.
In 2010, the global biologics market was valued at an estimated $149 billion. By 2015, it is expected to reach $239 billion, Baker said. The global injectable drug market was valued at $22 billion in 2012, and is expected to double in five years. Read More >